- Home
- ARQT vs TBLA Comparison
ARQT vs TBLA Comparison
Compare ARQT & TBLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- TBLA
- Stock Information
- Founded
- ARQT 2016
- TBLA 2007
- Country
- ARQT United States
- TBLA United States
- Employees
- ARQT N/A
- TBLA N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- TBLA Computer Software: Programming Data Processing
- Sector
- ARQT Health Care
- TBLA Technology
- Exchange
- ARQT Nasdaq
- TBLA Nasdaq
- Market Cap
- ARQT 1.1B
- TBLA 1.2B
- IPO Year
- ARQT 2020
- TBLA N/A
- Fundamental
- Price
- ARQT $13.08
- TBLA $3.63
- Analyst Decision
- ARQT Strong Buy
- TBLA Strong Buy
- Analyst Count
- ARQT 5
- TBLA 4
- Target Price
- ARQT $17.00
- TBLA $5.31
- AVG Volume (30 Days)
- ARQT 2.0M
- TBLA 669.5K
- Earning Date
- ARQT 02-25-2025
- TBLA 02-26-2025
- Dividend Yield
- ARQT N/A
- TBLA N/A
- EPS Growth
- ARQT N/A
- TBLA N/A
- EPS
- ARQT N/A
- TBLA N/A
- Revenue
- ARQT $138,708,000.00
- TBLA $1,694,954,000.00
- Revenue This Year
- ARQT $209.03
- TBLA $24.12
- Revenue Next Year
- ARQT $49.00
- TBLA $15.84
- P/E Ratio
- ARQT N/A
- TBLA N/A
- Revenue Growth
- ARQT 182.84
- TBLA 21.84
- 52 Week Low
- ARQT $3.59
- TBLA $2.87
- 52 Week High
- ARQT $16.20
- TBLA $5.00
- Technical
- Relative Strength Index (RSI)
- ARQT 46.24
- TBLA 46.80
- Support Level
- ARQT $12.61
- TBLA $3.43
- Resistance Level
- ARQT $14.36
- TBLA $3.62
- Average True Range (ATR)
- ARQT 0.98
- TBLA 0.13
- MACD
- ARQT -0.32
- TBLA -0.02
- Stochastic Oscillator
- ARQT 13.09
- TBLA 36.04
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About TBLA Taboola.com Ltd.
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, Germany, France, Rest of the world whilst it generates the majority of its revenue from the United States.